Early Improvement of Acute Respiratory Distress Syndrome in Patients With COVID-19 in the Intensive Care Unit: Retrospective Analysis
- PMID: 33630743
- PMCID: PMC7945975
- DOI: 10.2196/24843
Early Improvement of Acute Respiratory Distress Syndrome in Patients With COVID-19 in the Intensive Care Unit: Retrospective Analysis
Abstract
Background: Since the start of the COVID-19 pandemic, there have been over 2 million deaths globally. Acute respiratory distress syndrome (ARDS) may be the main cause of death.
Objective: This study aimed to describe the clinical features, outcomes, and ARDS characteristics of patients with COVID-19 admitted to the intensive care unit (ICU) in Chongqing, China.
Methods: The epidemiology of COVID-19 from January 21, 2020, to March 15, 2020, in Chongqing, China, was analyzed retrospectively, and 75 ICU patients from two hospitals were included in this study. On day 1, 56 patients with ARDS were selected for subgroup analysis, and a modified Poisson regression was performed to identify predictors for the early improvement of ARDS (eiARDS).
Results: Chongqing reported a 5.3% case fatality rate for the 75 ICU patients. The median age of these patients was 57 (IQR 25-75) years, and no bias was present in the sex ratio. A total of 93% (n=70) of patients developed ARDS during ICU stay, and more than half had moderate ARDS. However, most patients (n=41, 55%) underwent high-flow nasal cannula oxygen therapy, but not mechanical ventilation. Nearly one-third of patients with ARDS improved (arterial blood oxygen partial pressure/oxygen concentration >300 mm Hg) in 1 week, which was defined as eiARDS. Patients with eiARDS had a higher survival rate and a shorter length of ICU stay than those without eiARDS. Age (<55 years) was the only variable independently associated with eiARDS, with a risk ratio of 2.67 (95% CI 1.17-6.08).
Conclusions: A new subphenotype of ARDS-eiARDS-in patients with COVID-19 was identified. As clinical outcomes differ, the stratified management of patients based on eiARDS or age is highly recommended.
Keywords: ARDS; COVID-19; Chongqing; acute respiratory distress syndrome; characteristic; critically ill; epidemiology; improvement; intensive care unit; mortality; outcome.
©Zhu Zhan, Xin Yang, Hu Du, Chuanlai Zhang, Yuyan Song, Xiaoyun Ran, An Zhang, Mei Yang. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 09.03.2021.
Conflict of interest statement
Conflicts of Interest: None declared.
Figures

Similar articles
-
Outcomes of patients with COVID-19 acute respiratory distress syndrome requiring invasive mechanical ventilation admitted to an intensive care unit in South Africa.S Afr Med J. 2022 Feb 2;112(1):13516. S Afr Med J. 2022. PMID: 35140002
-
High flow nasal cannula oxygenation in COVID-19 related acute respiratory distress syndrome: a safe way to avoid endotracheal intubation?Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211019555. doi: 10.1177/17534666211019555. Ther Adv Respir Dis. 2021. PMID: 34057844 Free PMC article.
-
Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study.Intensive Care Med. 2021 Jan;47(1):60-73. doi: 10.1007/s00134-020-06294-x. Epub 2020 Oct 29. Intensive Care Med. 2021. PMID: 33211135 Free PMC article.
-
Immunonutrition for acute respiratory distress syndrome (ARDS) in adults.Cochrane Database Syst Rev. 2019 Jan 24;1(1):CD012041. doi: 10.1002/14651858.CD012041.pub2. Cochrane Database Syst Rev. 2019. PMID: 30677127 Free PMC article.
-
Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: a systematic review and meta-analysis.Expert Rev Respir Med. 2021 Oct;15(10):1347-1354. doi: 10.1080/17476348.2021.1920927. Epub 2021 May 5. Expert Rev Respir Med. 2021. PMID: 33882768 Free PMC article.
Cited by
-
Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review.Cytokine Growth Factor Rev. 2022 Feb;63:34-43. doi: 10.1016/j.cytogfr.2022.01.001. Epub 2022 Jan 13. Cytokine Growth Factor Rev. 2022. PMID: 35115233 Free PMC article. Review.
-
The MiR-320 Family Is Strongly Downregulated in Patients with COVID-19 Induced Severe Respiratory Failure.Int J Mol Sci. 2021 Sep 26;22(19):10351. doi: 10.3390/ijms221910351. Int J Mol Sci. 2021. PMID: 34638691 Free PMC article.
References
-
- Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar 19;91(1):157–160. doi: 10.23750/abm.v91i1.9397. http://europepmc.org/abstract/MED/32191675 - DOI - PMC - PubMed
-
- Weekly epidemiological update - 19 January 2021. World Health Organization. 2021. Jan 19, [2021-03-05]. https://www.who.int/publications/m/item/weekly-epidemiological-update---....
-
- Li X, Ma X. Acute respiratory failure in COVID-19: is it "typical" ARDS? Crit Care. 2020 May 06;24(1):198. doi: 10.1186/s13054-020-02911-9. https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02911-9 - DOI - DOI - PMC - PubMed
-
- Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang F. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020 Apr;8(4):420–422. doi: 10.1016/S2213-2600(20)30076-X. http://europepmc.org/abstract/MED/32085846 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials